“Molecular Prognostic Risk Signature Accurately Stratifies Acute Myeloid Leukemia Outcomes with N/KRAS and TP53 Mutations Negatively Impacting”

https://pubmed.ncbi.nlm.nih.gov/38113472

A new molecular prognostic risk signature accurately stratifies outcomes for acute myeloid leukemia patients treated with hypomethylating agents and venetoclax, with N/KRAS and TP53 mutations negatively impacting outcomes.